Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04247126 · ClinicalTrials.gov registry record · Phase 1
A Study of SY 5609, a Selective CDK7 Inhibitor, in Advanced Solid Tumors
A Phase 1 study of Breast Cancer and Pancreatic Cancer, sponsored by Syros Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 105
- Enrollment target
- 16
- Study locations
NCT04247126 is a Phase 1 study of Breast Cancer and Pancreatic Cancer that has completed, run by Syros Pharmaceuticals. The registered enrollment target is 105 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (96% lower). The trial reports 16 study locations across 13 states.
The verdict
NCT04247126, a Phase 1 study of Breast Cancer and Pancreatic Cancer, has completed, sponsored by Syros Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 105 participants
- Enrollment target
- 16
- Study locations
Study Summary
The study consists of 2 parts. Part 1 is dose escalation and will first administer SY-5609 alone to participants with select advanced solid tumors and then in combination with fulvestrant to participants with HR positive, HER2-negative breast cancer. Part 2 is a dose expansion and will first administer SY-5609 in combination with gemcitabine and then SY-5609 in combination with gemcitabine and nab-paclitaxel in participants with pancreatic ductal adenocarcinoma (PDAC) .
Conditions Studied
Interventions
- DRUG Fulvestrant
- DRUG Gemcitabine
- DRUG Nab-paclitaxel
- DRUG SY-5609
Study Locations (16)
California
- Cedars-Sinai Medical Center - Los Angeles
- University of California Los Angeles - Los Angeles
Massachusetts
- Massachusetts General Hospital - Boston
- Dana Farber Cancer Institute - Boston
Michigan
- University of Michigan - Ann Arbor
- START Midwest, LLC - Grand Rapids
Arizona
- Banner MD Anderson Cancer Center - Gilbert
Florida
- Orlando Health Cancer Institute - Orlando
Georgia
- Emory University - Atlanta
Iowa
- The University of Iowa - Iowa City
Maryland
- Johns Hopkins University - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 105 participants |
| Start Date | 2020-01-23 |
| Est. Completion | 2023-03-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04247126
The ClinicalTrials.gov registry entry for NCT04247126 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 105 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (96% lower). The listed sponsor is Syros Pharmaceuticals, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Breast Cancer appearing as the primary indexed condition, and to 4 interventions - of which Fulvestrant is the first listed.
NCT04247126 reports 16 study locations spanning 13 distinct geographic areas - top geographies include California, Massachusetts, Michigan.
Frequently Asked Questions
What is clinical trial NCT04247126 about?
NCT04247126 is a clinical study titled "A Study of SY 5609, a Selective CDK7 Inhibitor, in Advanced Solid Tumors". The study consists of 2 parts. Part 1 is dose escalation and will first administer SY-5609 alone to participants with select advanced solid tumors and then in combination with fulvestrant to participants with HR positive, HER2-negative breast cancer. Part 2 is a dose expansion and will first adminis...
What is the current status of trial NCT04247126?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 105 participants. The study started on 2020-01-23. Estimated completion is 2023-03-30.
What conditions does trial NCT04247126 study?
This clinical trial studies the following conditions: Breast Cancer, Pancreatic Cancer, Advanced Solid Tumor, Small-cell Lung Cancer.
What interventions are being tested in trial NCT04247126?
The interventions under investigation include: Fulvestrant (DRUG), Gemcitabine (DRUG), Nab-paclitaxel (DRUG), SY-5609 (DRUG).
Who is sponsoring clinical trial NCT04247126?
This trial is sponsored by Syros Pharmaceuticals, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04247126 being conducted?
This trial has 16 study locations across Arizona, California, Florida, Georgia, Iowa. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
VS-6766+Abema+Fulv in Met HR+/HER- BC
RECRUITING · Phase 1
-
KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung Cancer
RECRUITING · Phase 1
-
Focused Ultrasound and Gemcitabine in Breast Cancer
RECRUITING · Phase 1
-
A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
RECRUITING · Phase 1
-
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.